Improving Endothelial Function with ACE Inhibitors: An Important Therapeutic Target After Coronary Interventions.
Adjuvant medical therapy plays a central role in the ongoing care of patients with coronary artery disease after percutaneous revascularization. The cardiac and vascular protective effects of angiotensin converting enzyme (ACE) inhibitors make these agents an attractive choice in this setting, especially in light of the HOPE study results. Mounting evidence suggests that ACE inhibitors exert their favorable effects at the cellular level by antagonizing angiotensin II and enhancing nitric oxide bioavailability and, in the process, restoring normal endothelial function.